On July 23, a federal advisory committee starts voting on whether seven peptides that Americans buy today in a legal gray zone should become drugs that pharmacies can legally make.
The Pharmacy Compounding Advisory Committee, which advises the FDA, meets July 23 and 24 at the agency's White Oak campus in Maryland. Over the two days it will take up seven substances and decide, one by one, whether each belongs on the 503A Bulk Drug Substances List. That list is the legal switch. A peptide on it can be ordered up by a licensed compounding pharmacy and mixed into a prescription for a named patient. A peptide off it cannot, at least not lawfully.
Day one covers BPC-157 ↗, a research peptide marketed for gut and tendon healing, TB-500 ↗, the synthetic fragment of thymosin beta-4 sold for tissue repair, MOTS-c ↗, a mitochondrial peptide tied to metabolism and exercise, and KPV ↗, a three-amino-acid anti-inflammatory fragment. Day two covers DSIP ↗, delta sleep-inducing peptide, which the agency lists under the name emideltide, the Russian nootropic Semax ↗, and the longevity peptide Epitalon ↗.
What makes this a story rather than a calendar entry is the direction of travel. The committee is not weighing a crackdown. It is weighing access. The Guardian reported ↗ that the meeting could ease restrictions on a group of drugs with a devoted following and thin evidence behind them, and that adding them to the 503A list would effectively legalize a thriving gray market. Right now most of these peptides move through online vendors that label vials "research use only," a phrase that keeps the seller outside the rules that govern medicines. A 503A listing pulls the molecule back inside those rules.
How the field got here is its own thread. In February, Health and Human Services Secretary Robert F. Kennedy Jr. signaled a softer line on compounded peptides, and by April 23 the FDA had pulled twelve peptides off its Category 2 restricted list, the bucket reserved for substances that raise significant safety questions. We covered that move and the distinction it turned on: coming off the restricted list is not the same as going onto the permitted one ↗. The July panel is the second half of that sentence. Removal cleared a roadblock. The 503A vote decides whether to pave the road.
The part worth slowing down on is that the committee is voting on seven molecules as if they were one category, and they are not. The evidence behind each is wildly uneven. BPC-157 and TB-500 are anchored almost entirely in animal studies and self-reported use, with little controlled human safety data. Semax is approved and prescribed in Russia, so it carries decades of real clinical exposure, just not the kind the FDA usually accepts. MOTS-c is a genuine human mitochondrial-derived peptide with active metabolic research, sold for goals that research never tested. KPV is a small fragment of a natural hormone with a clean anti-inflammatory rationale and almost no trial record. DSIP and Epitalon sit mostly in older Soviet-era literature. Putting all seven on one ballot flattens that range into a single yes-or-no, and the yes-or-no is what determines who can legally make them.
This is where the molecular detail stops being trivia. peptidemodel hosts a card for every one of the seven, each with its sequence, its receptor or mechanism where one is known, and its evidence tier. A reader who wants to know whether the molecule about to be voted onto a legal pathway has any human data behind it can check the card before the committee checks the box. For BPC-157 and TB-500, the cards make the thinness of that record hard to miss.
The public docket, FDA-2025-N-6895, is open, and written comments submitted through July 9 are slated to reach the committee before it votes. After that, seven peptides find out which side of the legal line they land on, and five more are already queued for a later panel before next February.